Moreover, the inhibitory effects of trametinib treatment on migration, invasion, and glycolysis in glioma cells, together with the induction of apoptosis, were abolished by PKM2 overexpression—indicating that trametinib treatment efficacy is dependent on PKM2 levels. The gene discussed is PKM; the disease is glioma.